Clinical Trial Update: Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Orelabrutinib in combination with the Polatuzumab vedotin-containing Pola-R-CHP regimen for untreated non-GCB diffuse large B-cell lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Orelabrutinib (orelabrutinib)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING